Healthcare company Tevogen Bio revealed on Wednesday that it has filed its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to develop a COVID-19 treatment using proprietary antigen specific T cell technology.
In partnership with Dr Neal Flomenberg, a renowned bone marrow transplant expert and chair of the Department of Medical Oncology at Thomas Jefferson University, the company plans to evaluate T cell technology to treat hospitalized COVID-19 patients.
Utilising Tevogen's proprietary immunotherapy platform and Dr Flomenberg's expertise in research and the transplantation of T cells, the partnership will conduct clinical trials of T cell treatments for COVID-19. The T cells will be generated in the laboratory and administered to the very ill Corona patients. The body generates specific T cells to rid itself of viruses including COVID-19 in normal circumstances.
Additionally, Yale-trained infectious disease epidemiologist Dr Ryan Saadi is leading the company's efforts to develop a COVID-19 curative treatment.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial